Pulmonary Regurgitation
14
4
8
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
7%
1 trials in Phase 3/4
133%
4 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (14)
Berlin Registry of Right Heart Interventions
Harmony TPV Post-Approval Study
ALTERRA Post-Approval Study
ALTERRA: SAPIEN 3 THV With the Alterra Adaptive Prestent
The Medtronic Harmony™ Transcatheter Pulmonary Valve Clinical Study
Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial
VenusP-Valve Pivotal Study (PROTEUS STUDY)
Implantation of the Venus P-Valve™ in the Pulmonic Position in Patients With Native Outflow Tracts
Right Ventricular Diastolic Function in Chronic Adverse RV Loading And Congenital Heart Disease
COMPASSION - COngenital Multicenter Trial of Pulmonic VAlve Regurgitation Studying the SAPIEN InterventIONal THV
Early Versus Later Re-valving in Tetralogy of Fallot With Free Pulmonary Regurgitation
Pulmonic Valve REplacement Multi-discIpline EMEA Registry
Pulmonary Artery Repair With Covered Stents
Multi-center Trial of Percutaneous Pulmonary Valve Implantation With Venus-p